CRLCHARLES RIVER LABORATORIES INTERNATIONAL, INC.vs its industry peers
A metric-by-metric comparison of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. against iShares Biotechnology ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRLEsta | $13.0B#13 | — | 4.6x#3 | 3.2x#2 | -0.9%#12 | -750.1%#14 | 0.6%#10 | -5.1%#9 | 0.6%#9 | — | 79.0%#3 | — |
| VRTX | $130.4B#4 | 30.0x#5 | 6.4x#4 | 10.9x#7 | 8.9%#8 | 838.1%#3 | 34.8%#2 | 19.5%#5 | 25.0%#5 | — | 31.0%#9 | — |
| AMGN | $203.1B#2 | 23.3x#4 | 17.4x#8 | 5.5x#4 | 10.0%#7 | 88.5%#6 | 24.7%#7 | 66.0%#2 | 15.1%#6 | — | 40.3%#6 | 2.5%#1 |
| GILD | $181.4B#3 | — | 15.3x#6 | 6.2x#5 | 2.4%#9 | 1672.9%#2 | 34.0%#3 | 71.9%#1 | 26.7%#4 | — | 32.9%#8 | 2.2%#2 |
| REGN | — | 19.1x#2 | — | — | 1.0%#11 | 2.1%#9 | 24.9%#6 | 14.2%#6 | 9.4%#8 | — | 35.0%#7 | — |
| ARGX | $60.6B#5 | — | — | 1705.6x#12 | 254.4%#1 | 55.1%#7 | 2965.7%#1 | — | — | — | 29.4%#10 | — |
| ALNY | $31.9B#10 | 41.5x#6 | 23.5x#9 | 8.6x#6 | 65.2%#3 | 212.8%#4 | 13.5%#8 | 23.2%#3 | 150.5%#1 | — | — | — |
| NTRA | $50.6B#7 | — | 27.8x#10 | 21.9x#8 | 35.9%#5 | -9.3%#10 | -13.4%#11 | -11.4%#10 | -18.0%#10 | — | 103.6%#2 | — |
| RVMD | $43.9B#8 | — | 16.9x#7 | — | — | -88.5%#13 | — | -43.4%#12 | — | — | — | — |
| BIIB | $31.9B#9 | 23.2x#3 | 2.2x#1 | 3.2x#1 | 2.2%#10 | -20.8%#11 | 28.7%#5 | 8.7%#7 | 13.0%#7 | 4#2 | 50.8%#4 | — |
| MRNA | $57.4B#6 | — | 8.5x#5 | 29.5x#9 | -39.9%#13 | 20.8%#8 | -158.1%#12 | -41.7%#11 | -54.6%#11 | — | 501.9%#1 | — |
| INSM | $26.2B#11 | — | 34.6x#11 | 43.2x#10 | 66.7%#2 | -39.7%#12 | -205.6%#13 | -168.6%#13 | -163.0%#12 | 3#3 | -16.2%#11 | — |
| ONC | $511.7B#1 | 805.0x#7 | 98.9x#12 | 95.8x#11 | 40.2%#4 | 144.5%#5 | 8.4%#9 | 5.5%#8 | 29.9%#3 | 6#1 | — | — |
| INCY | $24.3B#12 | 17.2x#1 | 4.3x#2 | 4.7x#3 | 21.2%#6 | 3846.9%#1 | 29.5%#4 | 22.9%#4 | 49.0%#2 | — | 46.4%#5 | — |
Peer set: top holdings of IBB (iShares Biotechnology ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice